{"id":"NCT05070546","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-29","primaryCompletion":"2022-08-12","completion":"2022-08-12","firstPosted":"2021-10-07","resultsPosted":"2023-10-04","lastUpdate":"2025-05-25"},"enrollment":1124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infection Prevention"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.RSV.preF-based Vaccine","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)","type":"EXPERIMENTAL"},{"label":"C1 G2: Healthy Adults, 18-59 Years (Placebo)","type":"PLACEBO_COMPARATOR"},{"label":"C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)","type":"EXPERIMENTAL"},{"label":"C2 G4: High Risk Adult, 18-59 Years (Placebo)","type":"PLACEBO_COMPARATOR"},{"label":"C3 G5: Adults, 65 Years and Older (RSV Vaccine)","type":"EXPERIMENTAL"},{"label":"C3 G6: Adults, 65 Years and Older (Placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.","primaryOutcome":{"measure":"Cohorts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs)","timeFrame":"7 days after vaccination on Day 1 (Day 8)","effectByArm":[{"arm":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","deltaMin":273,"sd":null},{"arm":"Group 2 (Cohort 1): Placebo","deltaMin":10,"sd":null},{"arm":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","deltaMin":276,"sd":null},{"arm":"Group 4 (Cohort 2): Placebo","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":23,"countries":["United States","Belgium","Germany","Spain","Sweden"]},"refs":{"pmids":["39971605","39536455"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":319},"commonTop":["Chills","Nasopharyngitis","Covid-19","Vomiting","Headache"]}}